Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 11;11:5804. doi: 10.1038/s41598-021-83930-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Day-7 Safety analysis of the vaccine candidates, SK-01 V1, and OZG-3861 V1. (A) In vivo inactivated vaccine candidate treatments and euthanizations. Experimental plan of in vivo SK-01 V1 and OZG-3861 V1 intradermal treatment as single or double dose. (B) Graph showing weight change during one week in groups; control, blue; adjuvant negative single-dose (OZG-3861 V1), red; adjuvant positive single-dose (SK-01 V1), green. (C) Bar graph showing hemogram analysis including RBC, WBC, and HGB levels in the groups. (D) Bar graph showing the change in platelet proportions between groups in one week. (E) Bar graph showing levels of total blood protein, albumin, and gamma-globulin (g/L) in the groups. Bar graphs showing levels of (F) ALT (U/L), (G) LDH (U/L) and (H) Ca (mmol/L) in the blood of mice groups. (I) Histopathologic analysis on day 7 of the lung, jejunum of intestine, liver, spleen, cerebellum, hippocampus, kidney, and skin. Purkinje neurons (arrow). The thin double-headed arrow is space, the thick arrow is a picnotic cell.

Day-7 Safety analysis of the vaccine candidates, SK-01 V1, and OZG-3861 V1. (A) In vivo inactivated vaccine candidate treatments and euthanizations. Experimental plan of in vivo SK-01 V1 and OZG-3861 V1 intradermal treatment as single or double dose. (B) Graph showing weight change during one week in groups; control, blue; adjuvant negative single-dose (OZG-3861 V1), red; adjuvant positive single-dose (SK-01 V1), green. (C) Bar graph showing hemogram analysis including RBC, WBC, and HGB levels in the groups. (D) Bar graph showing the change in platelet proportions between groups in one week. (E) Bar graph showing levels of total blood protein, albumin, and gamma-globulin (g/L) in the groups. Bar graphs showing levels of (F) ALT (U/L), (G) LDH (U/L) and (H) Ca (mmol/L) in the blood of mice groups. (I) Histopathologic analysis on day 7 of the lung, jejunum of intestine, liver, spleen, cerebellum, hippocampus, kidney, and skin. Purkinje neurons (arrow). The thin double-headed arrow is space, the thick arrow is a picnotic cell.